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INTRODUCTION
Inflammatory bowel disease (IBD) incidence and preva-
lence have increased since the middle of the 20th Century. 
Several studies indicated a dramatic rise of disease inci-
dence not only in Western countries but also in Asian coun-
tries.1,2 Until now, Asian physicians treating IBD patients 
have referred to consensus guidelines provided by Western 
committees. However, Asian physicians always consider 
whether IBD treatment and diagnosis in Asia should be per-
formed the same way as in Western countries because the 
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differences in genetic background and environmental fac-
tors between Asian and Western countries are great.3 In ad-
dition, the types of approved drugs differ even among Asian 
countries. Under complicated circumstances, Asian physi-
cians as well as Western physicians face common problems 
regarding what to do for patients with refractory IBD, such 
as second-line therapies for steroid-refractory UC and thera-
peutic strategies for refractory CD with loss of response to 
anti-tumor necrosis factor (TNF) therapies.
Thus, there is a growing need for a customized consensus 
for IBD treatment in Asian countries. For this purpose, the 
Asian Organization of Crohn’s and Colitis (AOCC) per-
formed a multinational survey of medical doctors who treat 
IBD patients in Asian countries.
Our intent is to establish optimal treatment guidelines for 
Asian IBD patients based on of data from a multinational 
survey of medical doctors treating IBD patients.
METHODS
Members of the IBD Study Group of Korean Association 
for the Study of Intestinal Diseases (KASID) developed a 
questionnaire between August 2013 and November 2013. It 
was composed of 4 domains: personal information (9 items), 
IBD diagnosis (18 items), IBD treatment (30 items), and 
quality of IBD care (36 items). KASID officers and colleagues 
in China (M.H.C.) and Japan (H.N.) peer-reviewed the ques-
tionnaire. The questionnaires are shown in the Appendix. 
Upon completion of the questionnaire, a web-based survey 
was conducted between 17 March 2014 and 12 May 2014.
RESULTS
1. Participant Characteristics
In total, 353 physicians from Korea, China, Japan, India, 
Hong Kong, Singapore, Taiwan, Malaysia, the Philippines, 
and Indonesia participated in this survey. Most respondents 
were gastroenterologists who worked in academic teaching 
hospitals.
2. UC Management
1) Initial Treatment of Mild to Moderate UC
For the treatment of mild to moderate UC, topical 5-ami-
nosalicylic acid (5-ASA) was most preferred, followed by 
oral 5-ASA. In patients with left-sided UC, oral 5-ASA was 
most preferred, followed by topical 5-ASA. Many physicians 
used oral 5-ASA in combination with topical 5-ASA. Among 
participants, Chinese physicians preferred to use topical 
and systemic steroids compared with physicians from other 
countries.
The treatment employed for mild to moderate extensive 
UC is shown in Fig. 1. Oral 5-ASA was most preferred, fol-
lowed by systemic steroids. In comparison with treatment 
for left-sided UC and proctitis, systemic steroid use was pre-
ferred, although physicians might consider cases refractory 
to oral and topical 5-ASA. 
2) Treatment of Acute Severe UC
It is very important that physicians cooperate with sur-
geons when managing acute severe UC. Regarding surgical 
consultation at treatment initiation for acute severe UC, phy-
sicians in China, Japan, and other countries always and usu-
ally consult surgeons, while physicians in Korea sometimes 
and rarely consult them. Data regarding this question are 
quite different between Korea and other Asian countries. 
We usually use intravenous (IV) steroids for acute severe 
UC; however, 69% and 28% of physicians judged the thera-
peutic response 3−5 days and 6−9 days after initiating IV ste-
roids, respectively (Fig. 2). Thus, 93% of physicians assessed 
steroid response as soon as possible because patients with 
acute severe UC sometimes require second-line therapy and 
surgical treatment. 
Regarding second-line therapy for patients with acute 
severe UC refractory to IV steroids, many physicians in Asia 
except Japan selected anti-TNF therapies, followed by cy-
closporine. On the other hand, Japanese physicians selected 
tacrolimus (TAC), followed by anti-TNF therapies. A few 
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Fig. 1. The treatment employed for mild to moderate extensive UC. 
5-ASA, 5-aminosalicylic acid.
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Japanese physicians selected apheresis therapies (Fig. 3).
3) Treatment of Steroid-dependent or Steroid-refrac-
tory UC
This question was regarding the treatment of steroid-
dependent UC. Many physicians in Asia favored the use of 
thiopurines. Overall, 78% of physicians selected thiopurines, 
and 11% of them selected anti-TNF therapies. Some Japa-
nese physicians (3% of all participants) selected TAC and 
apheresis. 
For steroid-refractory UC, many physicians in Asia except 
Japan selected anti-TNF therapies in combination with thio-
purines, while Japanese physicians selected TAC, followed 
by anti-TNF. Overall, 44% of participants selected anti-TNF 
for steroid-refractory UC.
Cytomegalovirus (CMV) and Clostridium difficile  infec-
tion are possible factors exacerbating UC flares. Regarding 
how concerned physicians are about these infections in 
cases of severe UC attacks, many physicians in China, Japan, 
and Korea always tested for CMV infection; however, only 
12% of other Asian physicians always tested for it. Overall, 
59% of physicians always checked for CMV infection in se-
vere UC. In C. difficile  infection, a similar tendency was ob-
served. Thus, most physicians in Asia are likely to consider 
the involvement of these infections in severe attacks of UC 
(Fig. 4).
4) Maintenance of Remission
When we use maintenance treatment with 5-ASA, ad-
herence to 5-ASA drugs is an important issue. This survey 
showed that many physicians seemed to prescribe 5-ASA 
two times or once daily. Overall, 54% and 15% of participants 
selected twice daily and once daily regimens, respectively. 
3. CD Management
1) Treatment of CD according to disease Involvement 
and Activity
For induction therapy in mild to moderate inflammatory 
small bowel CD, many Asian physicians considered the use 
of 5-ASA. Of note, survey data showed that more physicians 
in Japan and China selected nutritional therapy than those 
in Korea and other Asian countries. In addition, Japanese 
physicians did not prefer the corticosteroid use when treat-
ing patients with mild to moderate active small intestinal CD 
(Fig. 5). In cases of mild to moderate inflammatory colonic 
CD, a similar tendency was observed.
Regarding the treatment of severe inflammatory small 
bowel CD, 25% of participants selected prednisolone in 
combination with 5-ASA, followed by anti-TNF therapies 
(14%), nutritional therapy (14%), and thiopurines (13%). 
Only 3% of physicians selected budesonides. Physicians in 
Japan and China preferred anti-TNF therapies, while those 
in Korea preferred prednisolone. 
In treating severe inflammatory colonic CD, a similar 
tendency was observed. Physicians in Japan and China pre-
ferred anti-TNF, while those in Korea and other Asian coun-
tries preferred prednisolone for remission induction.
2) Treatment of CD according to Disease Course
These questions were regarding Asian physicians’ ap-
proach towards treating steroid-dependent or refractory CD. 
In cases of steroid-dependent CD, most physicians preferred 
to use thiopurine, followed by anti-TNF therapies. However, 
when treating steroid-refractory CD, physicians considered 
using anti-TNF agents. In particular, Japanese physicians 









Fig. 2. The time assessing response to intravenous steroids in acute 
severe UC.
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Fig. 3. Second-line therapies in acute severe UC when intravenous ste-
roids fail. TNF, tumor necrosis factor.
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We sometimes encounter cases of thiopurine-intolerant 
or refractory CD. Most physicians favored anti-TNF antibod-
ies. A few physicians in China and other countries selected 
methotrexate (MTX). 
3) Treatment with Anti-TNF agents in CD
Regarding combination therapy with anti-TNF antibodies 
and thiopurines or anti-TNF monotherapy for thiopurine-
naïve CD patients, overall, 15% of participants always pre-
ferred combination therapy and 41% usually preferred it. 
Interestingly, Japanese physicians preferred monotherapy 
compared with physicians from other countries (Fig. 6).
The duration of combination therapy is a clinically impor-
tant issue for physicians and patients because we are always 
concerned about its risks. Overall, 25% and 29% of Asian 
physicians tended to continue combination therapy for 6 
months and 1 year, respectively. In addition, Japanese physi-
cians strongly preferred to continue combination therapy for 
a longer time (>2 years) (Fig. 7).
When asked how to treat non-responders to anti-TNF 
therapies, all physicians agreed with dose escalation, fol-
lowed by changing to another anti-TNF agents. Interestingly, 
>40% of physicians in China favored checking serum trough 
levels of anti-TNF antibodies.
4) Maintenance of Remission
Most physicians favored combination therapy in CD pa-
tients whose remission was induced by anti-TNF therapies. 
In particular, Korean physicians favored combination thera-
py compared with physicians from other countries.







Fig. 5. Induction therapy in mild to moderate inflammatory small 
bowel CD. 5-ASA, 5-aminosalicylic acid.
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Fig. 4. Test for cytomegalovirus (CMV) 
and Clostridium difficile  infection in a 
severe UC attack.
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5) Monitoring
To monitor CD patients during treatments, most physi-
cians used clinical activity, blood tests, and colonoscopy 
for disease monitoring. As for other imaging modalities, a 
few physicians favored CT enterography (11%), followed by 
magnetic resonance (MR) enterography (6%).
When asked whether they monitored 6-thioguanine 
nucleotides and 6-methylmercaptopurine levels, serum inf-
liximab (IFX) levels, and antibodies to IFX (ATI), most physi-
cians answered “No.” These data indicated that facilities for 
routine monitoring of these values in Asia are limited.
6) Prerention of Post-operative Recurrence in CD
As to when physicians performed colonoscopy for post-
operative CD patients, most physicians performed it within 
1 year after the operation, even in patients who did not have 
abdominal symptoms related to CD flares. 
When asked what treatments they would consider in 
postoperative CD patients with moderate to severe endo-
scopic recurrence who had been treated with 5-ASA, many 
physicians selected thiopurine or anti-TNF agents. Japanese 
physicians preferred anti-TNF agents in comparison with 
thiopurines.
When asked what treatments they would consider in post-
operative CD patients with moderate to severe endoscopic 
recurrence who had been treated with a maximum thiopu-
rine dose, all Asian physicians agreed with additional use of 
anti-TNF agents. 
Regarding the treatment of postoperative CD patients 
with moderate to severe endoscopic recurrence who had 
been treated with anti-TNF therapies, all Asian physicians 
considered additional use of thiopurine, dose escalation, or 
shortened intervals of anti-TNF therapies.
DISCUSSION 
The present survey demonstrates that current therapeutic 
approaches and clinical management of IBD vary among 
Asian countries. First, this survey focused on UC treatment. 
All participants agreed with 5-ASA use for mild to moder-
ate UC as a first-line therapy with little difference among 
Asian countries. In the current survey, there was no ques-
tion regarding the optimal 5-ASA dose for induction and 
maintenance of remission or the 5-ASA types mainly used 
in their countries. However, meta-analysis data have already 
demonstrated that there do not appear to be any differences 
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in efficacy or safety among the various 5-ASA formulations.4 
In addition, a 2.4-g daily dosage appears to be a safe and ef-
fective induction therapy for patients with mild to moderate 
active UC. Patients with moderate disease may benefit from 
an initial dose of 4.8 g/day. Thus, although Asian physicians 
need a consensus on the optimal 5-ASA dosage for induc-
tion of remission and maintenance for UC patients, this sur-
vey showed that most physicians agreed with 5-ASA use as a 
first-line therapy. 
The survey data from question 10 showed that many 
physicians prescribe 5-ASA two times or once daily because 
they kept the patient’s adherence in mind. However, a meta-
analysis showed that adherence does not appear to be 
enhanced by once daily dosing in the clinical trial setting.4 
Whether once daily dosing of 5-ASA improves adherence in 
a community-based setting is unknown, and whether time-
decreasing prescriptions contribute to favorable effects for 
UC patients might depend on not only adherence but also 
mucosal concentration of 5-ASA.
Despite the development of several medical therapies, 
acute severe UC treatment is still challenging. All partici-
pants considered consulting surgeons when treating acute 
severe UC. Additionally, 93% of physicians assessed steroid 
response within 9 days. Taken together, these data suggested 
that many physicians felt the importance of cooperation 
with surgeons for starting severe acute UC treatment and the 
necessity of rapid decision-making in patients with UC who 
fail to respond to IV steroids. The next question concerned 
optimal second-line therapy for patients with acute severe 
UC refractory to IV steroids. In general, for patients with 
refractory acute severe UC, after initially using IV steroids 
for 5−7 days, possible treatment choices included either IV 
cyclosporine or IV IFX. Most physicians in Asia except Japan 
selected anti-TNF therapies, followed by cyclosporine. On 
the contrary, Japanese physicians favored TAC, followed 
by anti-TNF therapies. A few Japanese physicians selected 
apheresis therapies. These survey data strongly suggested 
a difference in available medical treatments among Asian 
countries. 
Which is better as a second-line therapy for steroid-refrac-
tory severe UC, anti-TNF therapy or calcineurin inhibitors 
(CIs)? Use of both cyclosoprine and IFX has appeared to 
be effective and safe as a rescue therapy compared to pla-
cebo in acute severe UC; however, data regarding head-to-
head comparisons of CIs and anti-TNF agents are limited 
and based on retrospective observational studies. Also, no 
prospective studies have compared the efficacy of TAC with 
IFX as a second-line therapy. Minami et al.5 retrospectively 
assessed the short-term outcomes of 29 severe UC patients 
treated with TAC or IFX and concluded that the effects of 
TAC are potentially similar to those of IFX on severe UC, 
despite the limited number of enrolled patients. Overall, the 
rescue effect of CIs (both cyclosporine and TAC) as second-
line therapies for severe UC refractory to IV corticosteroids 
is similar to that of IFX.6 However, how to optimally select 
CIs or IFX in such clinical settings remains unclear.
As for steroid-dependent UC, most physicians agree with 
the use of thiopurines for tapering corticosteroids. The 
thiopurines, azathioprine and its metabolite 6-mercapto-
purine, are purine analogs that effectively maintain remis-
sion in patients with IBD, particularly in steroid-refractory 
or steroid-dependent disease. All participants recognized 
that the effect of thiopurine on refractory IBD is apparent in 
clinical practice. Only a few prospective studies and meta-
analyses have been reported, although little is known about 
the long-term clinical outcomes of UC patients who initially 
responded to thiopurine treatment.7 Most importantly, when 
patients who are maintained in remission on azathioprine 
or 6-mercaptopurine discontinue their medications, a very 
high relapse rate of 70%−87% occurs.8-10 In this regard, our 
next step is to survey how to optimize the dose of thiopurine 
drugs and how long we should continue thiopurines for 
maintenance. To establish this, we might require votes re-
garding the adjustment of thiopurine dose as the European 
Crohn’s and Colitis Organization members did.11
Numerous case series have reported the involvement of 
CMV and C. difficile  infection in patients with severe UC 
refractory to standard immunosuppressive therapy because 
the prognosis of patients with UC complicated by these in-
fections is poor.12 Survey data demonstrated that more than 
half of physicians in China, Japan, and Korea always tested 
for CMV and C. difficile  infection in refractory UC cases. 
CMV is often overlooked in refractory UC cases, and it is of 
particular importance to have an expert pathologist carefully 
examine mucosal biopsies for evidence of this pathogen. 
However, previous survey data showed that many physi-
cians diagnosed CMV infection with antigenemia assay,13 
although many experts recognized that CMV antigenemia 
assay was not necessarily useful for the decision to start anti-
viral therapy. As reported previously, the sensitivity of CMV 
diagnosis with histopathology in biopsy specimens was 
relatively low.14 Therefore, we always encounter a dilemma 
regarding diagnosis of CMV infection in refractory UC pa-
tients. Unfortunately, the questions of this survey did not 
include diagnostic criteria regarding CMV infection. In the 
future, we will need a consensus on the diagnosis of CMV 
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infection in Asia. This is a big issue for clinical practice.
Survey data regarding induction therapy for mild to mod-
erate inflammatory small bowel CD showed that many 
Asian physicians first selected 5-ASA. Of note, this survey re-
vealed that more physicians in Japan and China selected nu-
tritional therapy than those in Korea and other Asian coun-
tries. Safety and therapeutic efficacy of nutritional therapy 
for CD patients is well known, despite no placebo-controlled 
trial data.15 Whether physicians select nutritional therapy 
depends on patients’ acceptability, convenience, and adher-
ence. Treatment for severe inflammatory small bowel CD 
varied among the countries. Overall, 25% of participants 
selected prednisolone in combination with 5-ASA, followed 
by anti-TNF therapies, nutritional therapy, and thiopurines. 
Only 3% of physicians selected budesonides, which might 
differ from the tendency in Western countries. Also, the use 
of budesonide might be limited to the countries whose gov-
ernments permit its use. Of note, physicians in Japan and 
China selected anti-TNF therapies, while those in Korea se-
lected prednisolone. In treating severe inflammatory colonic 
CD, a similar tendency was observed. Overall, physicians in 
Japan and China preferred to use anti-TNF therapies, while 
those in Korea and other Asian countries preferred prednis-
olone for remission induction. The reason why preferences 
differed in remission induction among Asian countries re-
mains unclear. 
Treatments for steroid-dependent and refractory CD were 
thiopurine drugs and anti-TNF agents, which Asian physi-
cians selected first. These results were similar to those for UC 
treatment. Recently, data from Western countries suggested 
the following factors as potential predictors of an aggressive 
disease course in CD: age <40 years at diagnosis, presence of 
perianal lesions, early need for steroids, severe endoscopic 
lesions, and the existence of NOD2/CARD15 mutation.16-19 
In these cases, Western physicians would recommend top-
down therapy with anti-TNF antibodies. Therefore, in AOCC, 
Asian physicians cooperate to identify the risk factors in 
which poor prognoses of Asian CD patients are involved to 
determine who requires early anti-TNF therapies.
Most physicians favored combination therapy in CD 
patients whose remission was induced by anti-TNF thera-
pies. In particular, Korean physicians favored combination 
therapy compared with physicians in other countries. Also, 
Japanese physicians strongly preferred to continue combi-
nation therapy for more time. However, the optimal duration 
of combination anti-TNF therapies and thiopurine for CD 
remains unclear. The use of anti-TNF antibodies has sig-
nificantly impacted the management of CD patients. Most 
efficacy data with these agents are limited to those collected 
during relatively short-term (up to 1 year) clinical trials. 
Because of the chronic relapsing and progressive nature of 
CD, clinical trial data over longer durations of treatment are 
desirable to demonstrate both long-term efficacy and safety 
of these agents.
Considering several risks of combination therapy, mono-
therapy might be favorable after remission induction with 
combination therapy. However, the outcome of anti-TNF 
therapy cessation for CD in clinical and/or endoscopic re-
mission in routine clinical practice is uncertain. Louis et al. 
reported that approximately 50% of 115 patients with CD 
who were treated for at least 1 year with IFX and an antime-
tabolite agent experienced a relapse within 1 year after IFX 
discontinuation. In addition, they commented that patients 
with a low risk of relapse can be identified using a combina-
tion of clinical and biologic markers.20
Brooks et al. also reported that relapse rates at 1 year fol-
lowing elective withdrawal of anti-TNF were 36%, with high 
retreatment response rates. Predictors of relapse include 
ileocolonic involvement, previous anti-TNF therapy, and 
raised fecal calprotectin.21 As mentioned previously, we will 
need to identify several factors (clinical and biologic mark-
ers) that contribute to the cessation of anti-TNF therapies in 
CD patients in the future. 
A recent critical issue is the therapeutic strategy for treat-
ing CD patients who lose response to anti-TNF therapy. 
Also, no consensus exists regarding therapies for patients 
with CD refractory to anti-TNF therapy and thiopurines. All 
physicians considered dose escalation, followed by chang-
ing to another anti-TNF agent.22,23 In cases refractory to a 
standard regimen of anti-TNF therapies, a pharmacokinetic 
study measuring serum trough levels of anti-TNF antibodies, 
ATI, and anti-adalimumab antibodies will be required in the 
future, as >40% of the participants in China checked serum 
trough levels of anti-TNF antibodies. The survey results for 
question 5-3 and 5-4 showed that most physicians could 
not check serum trough levels of IFX, ATI, and 6TG levels 
in RBC. However, this monitoring is essential for optimizing 
treatment for individual IBD patients.
To monitor CD patients, many physicians used clinical ac-
tivity, blood tests, and colonoscopy for disease monitoring. 
On imaging modalities for evaluating small intestinal lesions, 
physicians favored CT enterography, followed by 6-thiogua-
nine nucleotides enterography. These data suggested that 
many Asian physicians were not familiar with using MR 
enterography to follow CD patients. However, the sensitiv-
ity and specificity of MRI for the detection of active disease 
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and correlation with segmental endoscopic disease severity 
and detection of complications are high, with >80% sensi-
tivity and >90% specificity. MRI also has been a valuable 
tool in the assessment of response to therapy; pathological 
improvements in MRI scans related to disease activity are 
responsive and reliable indicators of endoscopic healing.24,25 
Considering the radiation exposure by CT enterography, 
MRI might become the first modality for evaluating small 
intestinal lesions in CD patients. However, accumulation of 
more clinical data regarding the advantage of MRI as an im-
aging modality is necessary.
Postoperative management of CD patients is very impor-
tant to avoid repeated surgery.26,27 Most physicians recognize 
the necessity of early detection of endoscopic recurrence 
in postoperative CD patients with no clinical symptoms be-
cause they consider performing colonoscopic examination 
within 1 year after the operation. In addition, survey data 
regarding medical treatments in cases of postoperative CD 
with moderate to severe endoscopic recurrence showed that 
Asian physicians considered using thiopurine or anti-TNF 
agents, although Japanese physicians preferred to use anti-
TNF agents in comparison with thiopurines. In cases of post-
operative CD patients with moderate to severe endoscopic 
recurrence who have been treated with anti-TNF antibodies, 
all Asian physicians selected additional thiopurine use, dose 
escalation, or shortened intervals of anti-TNF treatment. 
It is natural that most physicians agree with the use of two 
medications for postoperative CD with moderate to severe 
endoscopic recurrence. In this regard, a future clinical issue 
is how to identify patients who need biologics, thiopurines, 
or both in postoperative CD.
In summary, the current survey results demonstrated the 
treatments of UC and CD in Asian countries, suggesting that 
most therapeutic strategies were coincident. Therefore, we 
should reach a consensus regarding the medical treatments 
of IBD on the basis of this survey. 
ACKNOWLEDGEMENT
The authors would like to thank all physicians in Asia join-
ing this wed-based survey. All authors have contributed to 
the creation of the questionnaire described in this article, 
and all authors participated in the preparation, review and 
approval of the manuscript content.
REFERENCES
1. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of 
inflammatory bowel disease based on results from the Asia-
pacific Crohn’s and colitis epidemiology study. Gastroenterol-
ogy 2013;145:158-165.
2. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflamma-
tory bowel disease in Asia: a systematic review. J Gastroenterol 
Hepatol 2012;27:1266-1280.
3. Ng SC, Tang W, Leong RW, et al. Environmental risk factors in 
inflammatory bowel disease: a population-based case-control 
study in Asia-Pacific. Gut 2015;64:1063-1071.
4. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induc-
tion of remission in ulcerative colitis. Cochrane Database Syst 
Rev 2012;10:CD000543. doi: 10.1002/14651858.CD000543.
pub3.
5. Minami N, Yoshino T, Matsuura M, et al. Tacrolimus or inflix-
imab for severe ulcerative colitis: short-term and long-term data 
from a retrospective observational study. BMJ Open Gastroen-
terol 2015;2:e000021. doi:10.1136/bmjgast-2014-000021.
6. Nakase H, Yoshino T, Matsuura M. Role in calcineurin inhibi-
tors for inflammatory bowel disease in the biologics era: when 
and how to use. Inflamm Bowel Dis 2014;20:2151-2156.
7. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Aza-
thioprine and 6-mercaptopurine for maintenance of re-
mission in ulcerative colitis. Cochrane Database Syst Rev 
2012;9:CD000478. doi: 10.1002/14651858.CD000478.pub3.
8. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised con-
trolled trial of azathioprine withdrawal in ulcerative colitis. BMJ 
1992;305:20-22.
9. Sandborn WJ. A review of immune modifier therapy for inflam-
matory bowel disease: azathioprine, 6-mercaptopurine, cyclo-
sporine, and methotrexate. Am J Gastroenterol 1996;91:423-
433.
10. Cuffari C, Present DH, Bayless TM, Lichtenstein GR. Optimiz-
ing therapy in patients with pancolitis. Inflamm Bowel Dis 
2005;11:937-946.
11. Travis SP, Stange EF, Lémann M, et al. European evidence-
based Consensus on the management of ulcerative colitis: cur-
rent management. J Crohns Colitis 2008;2:24-62.
12. Nakase H, Honzawa Y, Toyonaga T, et al. Diagnosis and treat-
ment of ulcerative colitis with cytomegalovirus infection: 
importance of controlling mucosal inflammation to prevent 
cytomegalovirus reactivation. Intest Res 2014;12:5-11.
13. Hida N, Nakamura S, Hahm KB, et al. A questionnaire-based 
survey on the diagnosis and management of inflammatory 
bowel disease in East Asian countries in 2012. Digestion 
2014;89:88-103.
http://dx.doi.org/10.5217/ir.2016.14.3.231 • Intest Res 2016;14(3):231-239
239www.irjournal.org
14. Yoshino T, Nakase H, Ueno S, et al. Usefulness of quantitative 
real-time PCR assay for early detection of cytomegalovirus in-
fection in patients with ulcerative colitis refractory to immuno-
suppressive therapies. Inflamm Bowel Dis 2007;13:1516-1521.
15. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional ther-
apy for induction of remission in Crohn’s disease. Cochrane 
Database Syst Rev 2007:CD000542. doi: 10.1002/14651858.
CD000542.pub2.
16. Louis E, Michel V, Hugot JP, et al. Early development of stric-
turing or penetrating pattern in Crohn’s disease is influenced 
by disease location, number of flares, and smoking but not by 
NOD2/CARD15 genotype. Gut 2003;52:552-557.
17. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. 
Long term outcome of patients with active Crohn’s disease ex-
hibiting extensive and deep ulcerations at colonoscopy. Am J 
Gastroenterol 2002;97:947-953.
18. Lakatos PL, Czegledi Z, Szamosi T, et al. Perianal disease, 
small bowel disease, smoking, prior steroid or early azathio-
prine/biological therapy are predictors of disease behavior 
change in patients with Crohn’s disease. World J Gastroenterol 
2009;15:3504-3510.
19. Dubinsky MC. Serologic and laboratory markers in prediction 
of the disease course in inflammatory bowel disease. World J 
Gastroenterol 2010;16:2604-2608.
20. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of re-
mission among patients with Crohn’s disease on antimetabolite 
therapy after infliximab therapy is stopped. Gastroenterology 
2012;142:63-70.
21. Brooks AJ, Sebastian S, Cross SS, et al. Outcome of elective 
withdrawal of anti-tumour necrosis factor-α therapy in patients 
with Crohn’s disease in established remission [published on-
line ahead of print May 18, 2015]. J Crohns Colitis. doi: 10.1016/
j.crohns.2014.09.007.
22. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and anti-
drug antibodies are associated with outcome of interventions 
after loss of response to infliximab or adalimumab. Clin Gastro-
enterol Hepatol 2015;13:522-530.
23. Guerra I, Bermejo F. Management of inflammatory bowel dis-
ease in poor responders to infliximab. Clin Exp Gastroenterol 
2014;7:359-367.
24. Panés J, Bouzas R, Chaparro M, et al. Systematic review: the 
use of ultrasonography, computed tomography and magnetic 
resonance imaging for the diagnosis, assessment of activity and 
abdominal complications of Crohn’s disease. Aliment Pharma-
col Ther 2011;34:125-145.
25. Ordás I, Rimola J, Rodríguez S, et al. Accuracy of magnetic reso-
nance enterography in assessing response to therapy and mu-
cosal healing in patients with Crohn’s disease. Gastroenterology 
2014;146:374-382.
26. Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J. System-
atic review: The use of thiopurines or anti-TNF in post-oper-
ative Crohn’s disease maintenance – progress and prospects. 
Aliment Pharmacol Ther 2014;39:1253-1265.
27. Baudry C, Pariente B, Lourenço N, et al. Tailored treatment 
according to early post-surgery colonoscopy reduces clinical 
recurrence in Crohn’s disease: a retrospective study. Dig Liver 
Dis 2014;46:887-892.
Appendix. Questionnaires regarding the treatment of IBD
Practice pattern for the treatment of ulcerative colitis 
[1] Initial treatment of mild to moderate UC
1-1. Which of the followings would you use to treat mild to moderate ulcerative proctitis?  
(Please choose all of the followings that you use)




1-2. Which of the followings would you use to treat mild to moderate left-sided active UC?  
(Please choose all of the followings that you use)




1-3. Which of the followings would you use to treat mild to moderately extensive UC?  
(Please choose all of the followings that you use)




[2] Treatment of acute severe UC 
2-1. How often do you seek consultation from a surgeon at the initiation of treatment for patients with acute severe UC? 
1) Always 2) Usually 3) Sometimes 4) Rarely 5) Never
2-2. When would you first assess response to intravenous corticosteroids therapy in patients with acute severe UC? 
1) On 3−5 days 2) On 6−9 days 3) On 10−14 days 4) After 14 days
2-3. Which of the followings would you consider 2nd-line therapy for acute severe UC patients who fail to improve on in-
travenous corticosteroids? 
1) Cyclosporine
2) Anti-TNF agent (infliximab or adalimumab)
3) Tacrolimus
4) Leukocytapheresis
5) Colectomy without changing medication 
6) Others (please specify,   )
[3] Treatment of steroid-dependent or steroid-refractory UC
3-1. Which of the followings would be your first choice for steroid-dependent UC? 
1) Repeated steroid regimens
2) Thiopurines (azathioprine or 6-mercaptopurine)
3) Anti-TNF agent (infliximab or adalimumab)
4) Tacrolimus
See “Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Orga-
nization of Crohn’s and Colitis (AOCC) meeting in Seoul” on page 231.
5) Leukocytapheresis
6) Colectomy
7) Others (please specify,   )
3-2. Which of the followings would be your first choice for steroid-refractory UC?
1) Repeated steroid regimens
2) Thiopurines (azathioprine or 6-mercaptopurine)




7) Others (please specify,   )
3-3. How often would you test for Cytomegalovirus (CMV) infection in a severe attack of UC?
1) Always 2) Usually 3) Sometimes 4) Rarely 5) Never
3-4. How often would you test for Clostridium difficile  infection in a severe attack of UC?
1) Always 2) Usually 3) Sometimes 4) Rarely 5) Never
[4] Maintenance of remission
4-1. How would you prescribe a regimen of oral 5-ASA for maintenance of remission in UC? 
1) Once daily 
2) Two times daily
3) Three times daily
4) Four times daily
Practice pattern for the treatment of Crohn’s disease 
[1] Treatment of CD according to disease involvement and disease activity
1-1. Which of the followings would you use for the first induction of remission in mild to moderate inflammatory small 
bowel CD (with or without colonic involvement)? (If you use combination therapy, please choose all of the follow-






6) Others (please specify,   )
1-2. Which of the followings would you use for the first induction of remission in mild to moderate inflammatory co-
lonic CD (without small bowel involvement)? (If you use combination therapy, please choose all of the followings 






6) Others (please specify,   )
1-3. Which of the followings would you use for the first induction of remission in moderate to severe inflammatory 
small bowel CD (with or without colonic involvement)? (If you use combination therapy, please choose all of the 







7) Anti-TNF agent 
8) Nutritional therapy
9) Others (please specify,   )
1-4. Which of the followings would you use for the first induction of remission in moderate to severe inflammatory co-










9) Others (please specify,   )
[2] Treatment of CD according to disease course





5) Others (please specify,   )





5) Others (please specify,   )




4) Others (please specify,   )
[3] Treatment with anti-TNF agents in CD
3-1. How often do you use thiopurine in combination with anti-TNF agents rather than anti-TNF monotherapy for induc-
tion of remission in thiopurine-naïve inflammatory CD?
1) Always 2) Usually 3) Sometimes 4) Rarely 5) Never
3-2. How long would you use combination therapy with anti-TNF agents and thiopurine for induction of remission?
1) 6 months 
2) 1 year 
3) 2years 
4) More than 2 years 
5) Others (please specify,   )
3-3. How would you treat non-responders to anti-TNF therapy?
1) I would make a decision according to the serum levels of anti-TNF agents and antibodies to anti-TNF agents.
2) I would use empiric dose escalation (double dosing or shortening of drug interval).
3) I would change to another anti-TNF agents.
4) Others (please specify,   )
[4] Maintenance of remission
4-1. Which of the followings would you use for maintenance of remission in CD patients whose remission has been in-







7) Anti-TNF agent 
8) Nutritional therapy
9) Others (please specify,   )
4-2. Which of the followings would you use for maintenance of remission in CD patients whose remission has been in-
duced with anti-TNF agents?
1) Anti-TNF agent only 
2) Thiopurine only
3) Combination therapy with anti-TNF agent and thiopurine
4) Others (please specify,   )
[5] Monitoring
5-1. What would you use for monitoring disease activity during treatment of CD? (Please choose all of the followings that 
you use) 
1) Clinical activity index 
2) Colonoscopy 
3) Video capsule endoscopy
4) Wired enteroscopy (balloon-assisted enteroscopy, sonde enteroscopy, or push enteroscopy)
5) Blood tests (CRP/ESR) 
6) Fecal calprotectin
7) Magnetic resonance enterography/enteroclysis
8) Computed tomographic enterography/enteroclysis
9) Bowel ultrasonography
10) Others (please specify,   )
5-3. Is it available to monitor the level of 6-TGN, 6-MMP in your practice? 
1) Yes 2) No
5-4. Is it available to monitor the level of serum infliximab and antibodies to infliximab in your practice? 
1) Yes 2) No
[6] Prevention of post-operative recurrence in CD
6-1. When would you perform colonoscopy after surgery in CD patients?
1) I seldom perform colonoscopy after surgery.
2) When clinical symptoms worsen
3) 6 months after surgery 
4) 12 months after surgery
5) Others (please specify,   )
6-2. Which of the followings would you use to treat postoperative CD patients with moderate to severe endoscopic re-
currence, who have been treated with 5-ASA? (If you use combination therapy, please choose all of the followings 





5) Others (please specify,   )
6-3. Which of the followings would you use to treat postoperative CD patients with moderate to severe endoscopic re-
currence, who have been treated with the maximal tolerable dose of thiopurine? (If you use combination therapy, 




4) Others (please specify,   )
6-4. Which of the followings would you use to treat postoperative CD patients with moderate to severe endoscopic re-
currence, who have been treated with an anti-TNF agent? (If you use combination therapy, please choose all of the 
following that you use)
1) Add thiopurine
2) Add metronidazole 
3) Maintain anti-TNF agent
4) Dose escalation or reduction of infusion intervals of anti-TNF agents
5) Others (please specify,   )
